Treatment-resistant Hypertension (RHTN)—Epidemiology Forecast—2034
Description
Key Highlights
Hypertension in adults (aged 18 years and older) is defined as having a systolic blood pressure of 140 mmHg or higher, a diastolic blood pressure of 90 mmHg or higher, or currently taking antihypertensive medication.
The evaluation of resistant hypertension begins with accurate blood pressure measurements, as improper techniques can result in falsely high readings. Automated Office Blood Pressure (AOBP) measurement with a specialized oscillometric device allows repeated blood pressure measurements.
As per estimates, overall 51% of people are suffering from hypertension in the US.
The prevalence of hypertension shows a clear positive correlation with age, meaning that the risk of developing high blood pressure increases significantly as people get older.
The diagnosed prevalence of TRH ranges from 10–14% across the 7MM, suggesting a consistent yet notable burden of the condition.
The number of diagnosed prevalent cases of TRH was slightly higher among females than males in the 7MM.
DelveInsight’s “Treatment Resistant Hypertension (TRH) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of TRH, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Treatment Resistant Hypertension (TRH) Understanding
Treatment Resistant Hypertension Overview
Resistant hypertension is defined as either uncontrolled blood pressure remaining at =130 mmHg Systolic Blood Pressure (SBP) and = 80 mm Hg Diastolic Blood Pressure (DBP) despite the concurrent prescription of three or four antihypertensive drugs of different classes or controlled blood pressure with the prescription of more than or equal to four antihypertensive drugs, with both definitions including a thiazide diuretic and all medications at maximally tolerated doses. Uncontrolled cases of elevated blood pressure in patients prescribed more than or equal to adequately dosed antihypertensive drugs, inclusive of a diuretic, will include both RHT and refractory hypertension. It is observed that people in whom blood pressure is controlled on more than three antihypertensive drugs may also benefit from a review in a specialist setting. This will ensure that pseudo-resistant and secondary hypertension are excluded and optimal drugs and doses are prescribed, thus avoiding potential over-treatment. Blood pressure is determined by complex interactions that occur among the Renin–Angiotensin–Aldosterone System (RAAS), the Sympathetic Nervous System (SNS), the endothelin system, natriuretic peptides, the arterial vasculature, and the immune system. Hypertension may result from dysfunction in any or all of these systems, with contributions from genetics, environmental factors (e.g., high sodium intake, low potassium intake, sleep apnea, excessive alcohol intake, physical inactivity, and stress), and aging. Hypertension often has no symptoms, making regular blood pressure checks essential. When extremely high (180/120 mm Hg or more), it can cause headaches, chest pain, dizziness, vision changes, shortness of breath, nausea, anxiety, nosebleeds, and irregular heartbeat. If untreated, it can lead to serious conditions like heart disease, stroke, and kidney damage.
Treatment Resistant Hypertension Diagnosis
Evaluating resistant hypertension starts with ensuring accurate blood pressure measurements, as errors like using the wrong cuff size or incorrect arm positioning can lead to falsely elevated readings. It's also crucial to rule out the white coat effect using ambulatory or home blood pressure monitoring that follows established guidelines. AOBP measurement, which uses a specialized oscillometric device to take repeated readings every 1–2 minutes while the patient sits alone in a quiet room, helps minimize this effect. A meta-analysis found AOBP results comparable to home monitoring, supporting its use for reducing the white coat effect. As per Hypertension Canada Guidelines, AOBP is the preferred method for office blood pressure measurement. Ultimately, true resistant hypertension can only be diagnosed if patients are confirmed to be taking their prescribed medications correctly.
Further details related to country-based variations are provided in the report…
Treatment Resistant Hypertension (TRH) Epidemiology
The TRH epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of treatment resistant hypertension, gender-specific diagnosed prevalent cases of treatment resistant hypertension, age-specific diagnosed prevalent cases of treatment resistant hypertension in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2020 to 2034.
In 2024, the total diagnosed prevalent cases of TRH in the United States were approximately 7 million cases, projected to increase during the forecast period (2025–2034).
In Japan, among the gender-specific diagnosed prevalent cases females had the slightly high contribution; ~55% in 2024, which is likely to increase to by 2034.
In the US in 2024, the highest diagnosed prevalence of TRH was observed in adults aged =60 group, while the lowest was in the 18–39 age group.
Treatment Resistant Hypertension (TRH) Report Insights
Treatment Resistant Hypertension (TRH) Report Insights
Patient population
Country-wise epidemiology distribution
Treatment Resistant Hypertension (TRH) Report Key Strengths
Ten years forecast
7MM coverage
TRH epidemiology segmentation
FAQs
What are the disease risks, burdens, and unmet needs of TRH? What will be the growth opportunities across the 7MM concerning the patient population with TRH?
What is the historical and forecasted TRH patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Which gender accounts for a higher proportion of diagnosed TRH cases?
How are diagnosed prevalent TRH cases distributed across different age groups?
Reasons to Buy
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
A detailed overview of age-specific and gender-specific cases of TRH is an inclusion.
Hypertension in adults (aged 18 years and older) is defined as having a systolic blood pressure of 140 mmHg or higher, a diastolic blood pressure of 90 mmHg or higher, or currently taking antihypertensive medication.
The evaluation of resistant hypertension begins with accurate blood pressure measurements, as improper techniques can result in falsely high readings. Automated Office Blood Pressure (AOBP) measurement with a specialized oscillometric device allows repeated blood pressure measurements.
As per estimates, overall 51% of people are suffering from hypertension in the US.
The prevalence of hypertension shows a clear positive correlation with age, meaning that the risk of developing high blood pressure increases significantly as people get older.
The diagnosed prevalence of TRH ranges from 10–14% across the 7MM, suggesting a consistent yet notable burden of the condition.
The number of diagnosed prevalent cases of TRH was slightly higher among females than males in the 7MM.
DelveInsight’s “Treatment Resistant Hypertension (TRH) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of TRH, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Treatment Resistant Hypertension (TRH) Understanding
Treatment Resistant Hypertension Overview
Resistant hypertension is defined as either uncontrolled blood pressure remaining at =130 mmHg Systolic Blood Pressure (SBP) and = 80 mm Hg Diastolic Blood Pressure (DBP) despite the concurrent prescription of three or four antihypertensive drugs of different classes or controlled blood pressure with the prescription of more than or equal to four antihypertensive drugs, with both definitions including a thiazide diuretic and all medications at maximally tolerated doses. Uncontrolled cases of elevated blood pressure in patients prescribed more than or equal to adequately dosed antihypertensive drugs, inclusive of a diuretic, will include both RHT and refractory hypertension. It is observed that people in whom blood pressure is controlled on more than three antihypertensive drugs may also benefit from a review in a specialist setting. This will ensure that pseudo-resistant and secondary hypertension are excluded and optimal drugs and doses are prescribed, thus avoiding potential over-treatment. Blood pressure is determined by complex interactions that occur among the Renin–Angiotensin–Aldosterone System (RAAS), the Sympathetic Nervous System (SNS), the endothelin system, natriuretic peptides, the arterial vasculature, and the immune system. Hypertension may result from dysfunction in any or all of these systems, with contributions from genetics, environmental factors (e.g., high sodium intake, low potassium intake, sleep apnea, excessive alcohol intake, physical inactivity, and stress), and aging. Hypertension often has no symptoms, making regular blood pressure checks essential. When extremely high (180/120 mm Hg or more), it can cause headaches, chest pain, dizziness, vision changes, shortness of breath, nausea, anxiety, nosebleeds, and irregular heartbeat. If untreated, it can lead to serious conditions like heart disease, stroke, and kidney damage.
Treatment Resistant Hypertension Diagnosis
Evaluating resistant hypertension starts with ensuring accurate blood pressure measurements, as errors like using the wrong cuff size or incorrect arm positioning can lead to falsely elevated readings. It's also crucial to rule out the white coat effect using ambulatory or home blood pressure monitoring that follows established guidelines. AOBP measurement, which uses a specialized oscillometric device to take repeated readings every 1–2 minutes while the patient sits alone in a quiet room, helps minimize this effect. A meta-analysis found AOBP results comparable to home monitoring, supporting its use for reducing the white coat effect. As per Hypertension Canada Guidelines, AOBP is the preferred method for office blood pressure measurement. Ultimately, true resistant hypertension can only be diagnosed if patients are confirmed to be taking their prescribed medications correctly.
Further details related to country-based variations are provided in the report…
Treatment Resistant Hypertension (TRH) Epidemiology
The TRH epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of treatment resistant hypertension, gender-specific diagnosed prevalent cases of treatment resistant hypertension, age-specific diagnosed prevalent cases of treatment resistant hypertension in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2020 to 2034.
In 2024, the total diagnosed prevalent cases of TRH in the United States were approximately 7 million cases, projected to increase during the forecast period (2025–2034).
In Japan, among the gender-specific diagnosed prevalent cases females had the slightly high contribution; ~55% in 2024, which is likely to increase to by 2034.
In the US in 2024, the highest diagnosed prevalence of TRH was observed in adults aged =60 group, while the lowest was in the 18–39 age group.
Treatment Resistant Hypertension (TRH) Report Insights
Treatment Resistant Hypertension (TRH) Report Insights
Patient population
Country-wise epidemiology distribution
Treatment Resistant Hypertension (TRH) Report Key Strengths
Ten years forecast
7MM coverage
TRH epidemiology segmentation
FAQs
What are the disease risks, burdens, and unmet needs of TRH? What will be the growth opportunities across the 7MM concerning the patient population with TRH?
What is the historical and forecasted TRH patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Which gender accounts for a higher proportion of diagnosed TRH cases?
How are diagnosed prevalent TRH cases distributed across different age groups?
Reasons to Buy
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
A detailed overview of age-specific and gender-specific cases of TRH is an inclusion.
Table of Contents
83 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Executive Summary
- 4. Key Events
- 5. Epidemiology and Market Forecast Methodology
- 6. TRH Market Overview at a Glance in the 7MM
- 6.1. Patient Share (%) Distribution of Treatment Resistant Hypertension (TRH) by Country in 2024
- 6.2. Patient Share (%) Distribution of Treatment Resistant Hypertension (TRH) by Country in 2034
- 7. Disease Background and Overview
- 7.1. Introduction
- 7.2. Symptoms
- 7.3. Risk Factors
- 7.4. Pathophysiology of TRH
- 7.5. Diagnosis
- 7.6. Treatment
- 7.7. Diagnostic Guidelines and Recommendations TRH
- 8. Epidemiology and Patient Population
- 8.1. Key Findings
- 8.2. Assumptions and Rationale
- 8.3. Total Diagnosed Prevalent Cases of TRH in the 7MM
- 8.4. The United States
- 8.4.1. Total Diagnosed Prevalent Cases of TRH in the United States
- 8.4.2. Gender-specific Diagnosed Prevalent Cases of TRH in the United States
- 8.4.3. Age-specific Diagnosed Prevalent Cases of TRH in the United States
- 8.5. EU4 and the UK
- 8.5.1. Total Diagnosed Prevalent Cases of TRH in EU4 and the UK
- 8.5.2. Gender-specific Diagnosed Prevalent Cases of TRH in EU4 and the UK
- 8.5.3. Age-specific Diagnosed Prevalent Cases of TRH in EU4 and the UK
- 8.6. Japan
- 8.6.1. Total Diagnosed Prevalent Cases of TRH in Japan
- 8.6.2. Gender-specific Diagnosed Prevalent Cases of TRH in Japan
- 8.6.3. Age-specific Prevalent Cases of TRH in Japan
- 9. Appendix
- 9.1. Bibliography
- 9.2. Report Methodology
- 10. DelveInsight Capabilities
- 11. Disclaimer
- 12. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
